(RTTNews) - Johnson & Johnson (JNJ), Thursday announced results from additional analyses of the Phase 2 DAHLIAS study, evaluating the effects of Nipocalimab in participants with primary Sjogren's ...

Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

On Tuesday, Johnson & Johnson (JNJ) stock saw a decline, ending the day at $152.64 which represents a decrease of $-2.40 or -1.55% from the prior close of $155.04. The stock opened at $154.53 and ...

Johnson & Johnson has a high three-year median payout ratio of 71% (or a retention ratio of 29%), meaning that the company is ...

HRSA’s threats of penalties led J&J to halt the plan, prompting a legal battle to protect its proposed changes. Johnson & ...

On Friday, Johnson & Johnson (JNJ) stock saw a decline, ending the day at $155.47 which represents a decrease of $-1.26 or -0.80% from the prior close of $156.73. The stock opened at $157 and touched ...

Amid current economic uncertainties and market volatility, investing in defensive stocks appears as an ideal strategy for ...

In my view, such adjustments are totally acceptable, and I shared my reasons - although obviously not directly comparable - ...

GET MORE AI-GENERATED SIGNALS: November 09, 2024, 09:42 am ET, BY Chris- Contributor| Editor: Thomas H. Kee Jr. ( Follow on ...

With the rise of chronic diseases, technological advances and innovative drug pipelines are driving significant growth in the ...

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments ...

There are no important events for this country at this time. Select "All" to see top events in other countries or view all events.